Department of Geriatrics, Sichuan University West China Hospital, Chengdu, Sichuan, China.
National Clinical Research Center for Geriatrics, Sichuan University West China Hospital, Chengdu, Sichuan, China.
BMJ Open. 2024 Mar 5;14(3):e078034. doi: 10.1136/bmjopen-2023-078034.
This review aims to provide an estimate of sarcopenia prevalence and its impact on clinical characteristics in patients with systemic sclerosis (SSc).
Systematic review and meta-analysis.
Embase, Medline, Web of Science and the Cochrane Central Register of Controlled Trials were systemically searched from inception to 24 May 2023.
We included observational studies that reported the prevalence of sarcopenia in patients with SSc.
Two reviewers independently performed study selection and data extraction using standardised methods. Risk of bias was assessed using the Agency for Healthcare Research and Quality Scale and the Newcastle-Ottawa Scale. Meta-analysis was conducted using random effects models.
A total of 4583 articles were screened and 9 studies with data from 815 patients were included in the analysis (8 cross-sectional studies and 1 retrospective cohort study). The overall prevalence of sarcopenia in patients with SSc was 22% (95% CI 17% to 28%). Patients with SSc with sarcopenia had a poorer quality of life (mean difference -12.02; 95% CI -19.11 to -4.93) and higher C reactive protein (CRP) levels (standardised mean difference 0.67; 95% CI 0.35 to 1.00).
Sarcopenia is common in patients with SSc. Patients with SSc with sarcopenia had a worse quality of life and higher CRP levels, based on our findings. Given the detrimental impact of sarcopenia on quality of life, future efforts aimed at early identification of sarcopenia in the clinical assessment of patients with SSc may have significance.
CRD42022368326.
本综述旨在评估肌少症在系统性硬化症（SSc）患者中的流行率及其对临床特征的影响。
系统综述和荟萃分析。
从建库到 2023 年 5 月 24 日，我们系统性地检索了 Embase、Medline、Web of Science 和 Cochrane 中央对照试验注册库。
我们纳入了报告 SSc 患者肌少症流行率的观察性研究。
两位审查员使用标准方法独立进行了研究选择和数据提取。使用美国卫生保健研究与质量局量表和纽卡斯尔-渥太华量表评估偏倚风险。使用随机效应模型进行荟萃分析。
共筛选出 4583 篇文章，有 9 项研究（8 项横断面研究和 1 项回顾性队列研究）的数据纳入分析，共纳入 815 例患者。SSc 患者肌少症的总体流行率为 22%（95%CI 17%至 28%）。患有肌少症的 SSc 患者生活质量较差（平均差异-12.02；95%CI-19.11 至-4.93），C 反应蛋白（CRP）水平较高（标准化均数差 0.67；95%CI 0.35 至 1.00）。
肌少症在 SSc 患者中较为常见。根据我们的研究结果，患有 SSc 且合并肌少症的患者生活质量更差，CRP 水平更高。鉴于肌少症对生活质量的不利影响，未来在 SSc 患者的临床评估中，针对肌少症的早期识别进行努力可能具有重要意义。
PROSPERO 注册号：CRD42022368326。
